Fennec Pharmaceuticals (TSE:FRX) Rating Increased to Strong-Buy at Stephens

Stephens upgraded shares of Fennec Pharmaceuticals (TSE:FRX) to a strong-buy rating in a research report sent to investors on Monday morning,Zacks.com reports.

Fennec Pharmaceuticals Stock Performance

Shares of TSE FRX opened at C$6.59 on Monday. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The stock has a market capitalization of C$180.30 million, a price-to-earnings ratio of 64.70 and a beta of 0.25. The stock’s fifty day simple moving average is C$6.40 and its 200 day simple moving average is C$7.99. Fennec Pharmaceuticals has a 52-week low of C$5.65 and a 52-week high of C$15.43.

Insider Activity

In other Fennec Pharmaceuticals news, Senior Officer Robert Christopher Andrade purchased 15,816 shares of the stock in a transaction dated Monday, November 18th. The shares were acquired at an average price of C$3.43 per share, for a total transaction of C$54,248.88. Over the last quarter, insiders have sold 6,268 shares of company stock worth $42,990. 16.20% of the stock is owned by corporate insiders.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.